Sticking by the strong relationship Moderna has fostered with the United Kingdom, the mRNA specialist is relocating its home base in the country to a different part of the capital.
The vaccine maker, which has its current U.K. headquarters on Victoria Street in London, will be picking up and moving its commercial HQ roughly a 15-minute ride on the tube north to King’s Cross.
The new site, slated to occupy the 4,206-square-foot Reflector building on the Tribeca campus, will be situated at the heart of the U.K. capital’s “Knowledge Quarter,” according to a Nov. 9 release from property development firm Reef + Partners and BlackRock Real Estate.
The space will be set up to a “fully fitted specification,” with the release noting that the headquarters will be designed in close collaboration with Moderna. Work to set up the biopharma’s operations in the building should be completed by the end of April 2027.
Moderna will be in good company at Tribeca, where London is striving to build out an innovation hub for the life sciences. The broader campus is being constructed in two phases, with the first establishing more than 110,000 square feet of lab space, some of which is already being used by the London BioScience Innovation Centre (LBIC) and the Francis Crick Institute.
"The U.K. is a key market for Moderna and expanding our footprint with space at Tribeca marks another step in our long-term commitment to the country’s vibrant life sciences ecosystem,” Darius Hughes, Moderna’s U.K. general manager, said in a statement.
“With Tribeca positioned at the heart of London’s Knowledge Quarter, it puts us in close proximity to many of the country’s leading scientific and research institutions, making it a great environment for our continued growth and the further development of our mRNA platform,” Hughes added.
Moderna's move is another welcome show of support for the U.K. after a tricky period that saw a wave of Big Pharmas pause or freeze funding a year ago over a dispute about drug reimbursement prices. They included Merck & Co., which vacated its laboratories at the Francis Crick Institute and abandoned the construction of a 1 billion pound sterling ($1.31 billion) R&D center on the edge of the Knowledge Quarter.
But policy moves since then, including a trade deal with the U.S. that has seen the U.K. pledge to increase its spending on innovative drugs, as well as the pricing benchmark used by the nation’s drug cost appraiser NICE, seem to have appeased at least some of those drugmakers. AstraZeneca, for instance, said in April that plans for a 200-million-pound project in its hometown of Cambridge would be restarted after it paused the work last fall, while AbbVie committed last week to spend 120 million pounds ($160 million) to expand its U.K. R&D presence.
Merck and Lilly, for their parts, have maintained a more frigid stance, with their projects still apparently on hold when Fierce reached out in September.
All the while, Moderna pushed ahead last year with the long-anticipated opening of a U.K. production facility in Harwell, dubbed the Moderna Innovation and Technology Centre, which debuted in late September 2025.
That site opened with the capacity to crank out upwards of 100 million mRNA vaccine doses per year, with the ability to boost that output in the event of a health emergency, and it also came equipped with laboratories to analyze samples from global clinical trials.
The site build-out marks a key facet in the 10-year commitment Moderna previously inked with the U.K, which was designed to improve the nation’s pandemic preparedness and incorporates a 1-billion-pound investment in local R&D, too.
Where Big Pharma is placing its bets is one of the hot topics being discussed at Fierce Biotech's high-impact event in London next month. Find out more information and register by clicking on the banner below:
